We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NURTEC ODT

News List

FDA Accepts sNDA Of NURTEC ODT for Preventive Treatment of Migraine americanpharmaceuticalreview
October 21, 2020
Biohaven Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for the preventive treatment of migraine.
Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment americanpharmaceuticalreview
March 18, 2020
Catalent welcomed the announcement by Biohaven the U.S. Food and Drug Administration (FDA) has approved its NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults.
Biohaven Wins FDA Approval for NURTEC ODT contractpharma
March 18, 2020
Developed in partnership with Catalent using its Zydis orally disintegrating tablet (ODT) technology.